Long-term outcome with all-trans retinoic acid (ATRA)-based regimens.
| Study . | n . | Regimen . | DFS/EFS/RFS, 3–5 yrs, (%) . |
|---|---|---|---|
| Abbreviations: DFS, disease-free survival; EFS, event-free survival; RFS, relapse-free survival; ATRA, all-trans retinoic acid; DNR, daunorubicin; Ara-C, cytosine arabinoside; IDA, idarubicin | |||
| Randomized | |||
| APL9135 | 54 | ATRA+DNR+Ara-C | 63 |
| North American Intergroup14,36 | 49 | ATRA+DNR+Ara-C+maint. | 74 |
| Nonrandomized | |||
| GIMEMA37 | 108 | ATRA+IDA+maint. | 90 |
| PETHEMA37 | 109 | ATRA+IDA+maint. (no Ara-C) | 90 |
| Study . | n . | Regimen . | DFS/EFS/RFS, 3–5 yrs, (%) . |
|---|---|---|---|
| Abbreviations: DFS, disease-free survival; EFS, event-free survival; RFS, relapse-free survival; ATRA, all-trans retinoic acid; DNR, daunorubicin; Ara-C, cytosine arabinoside; IDA, idarubicin | |||
| Randomized | |||
| APL9135 | 54 | ATRA+DNR+Ara-C | 63 |
| North American Intergroup14,36 | 49 | ATRA+DNR+Ara-C+maint. | 74 |
| Nonrandomized | |||
| GIMEMA37 | 108 | ATRA+IDA+maint. | 90 |
| PETHEMA37 | 109 | ATRA+IDA+maint. (no Ara-C) | 90 |